Stock listing
H1O Stock Price, News, Filings & Events — Vyome Holdings, Inc.
Selected listing: H1O · MUN · EUR · DE
This page tracks Vyome Holdings, Inc.'s H1O:MUN listing on MUN in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following H1O:MUN. H1O:MUN is the stock-level entry point for investors researching Vyome Holdings, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- H1O:MUN
- Asset type
- Stock
- Market cap
- $15.6M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- MUN
- Currency
- EUR
Vyome Holdings, Inc. H1O:MUN stock context
This page tracks Vyome Holdings, Inc.'s H1O:MUN listing on MUN in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following H1O:MUN. H1O:MUN is the stock-level entry point for investors researching Vyome Holdings, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Vyome Holdings, Inc.
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
September 14, 2026
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
May 28, 2026
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
May 12, 2026
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
April 22, 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
April 6, 2026
Vyome Holdings, Inc. earnings calls
ReShape Lifesciences, Inc. (RSLS) Q2 2024 Earnings Call
August 15, 2024 · Replay with transcript and chapters
ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call
May 15, 2024 · Replay with transcript and chapters
ReShape Lifesciences, Inc. (RSLS) Q4 2023 Earnings Call
April 1, 2024 · Replay with transcript and chapters
ReShape Lifesciences, Inc. (RSLS) Q3 2023 Earnings Call
November 8, 2023 · Replay with transcript and chapters
ReShape Lifesciences, Inc. (RSLS) Q2 2023 Earnings Call
August 7, 2023 · Replay with transcript and chapters
ReShape Lifesciences, Inc. (RSLS) Q1 2023 Earnings Call
May 15, 2023 · Replay with transcript and chapters
Research Vyome Holdings, Inc.
Vyome Holdings, Inc. investor report
Review AI stock analysis and investor report context for H1O:MUN.
Vyome Holdings, Inc. company profile
View the public company page for Vyome Holdings, Inc. on 6ix.
Vyome Holdings, Inc. news
Read company news and market updates connected to Vyome Holdings, Inc..
Vyome Holdings, Inc. investor events
Find investor webinars, events, and replay context for Vyome Holdings, Inc..
Alternate listings
HIND:NASDAQ
US · USD
Alternate listing for Vyome Holdings, Inc.; the primary context on this page is H1O:MUN.
HIND:BOATS
US · USD
Alternate listing for Vyome Holdings, Inc.; the primary context on this page is H1O:MUN.
H1O:GETTEX
DE · EUR
Alternate listing for Vyome Holdings, Inc.; the primary context on this page is H1O:MUN.